Dr. Jairam Krishnamurthy, MD
Claim this profileUniversity of Nebraska Medical Center
Area of expertise
Breast Cancer
Jairam Krishnamurthy, MD has run 10 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Jairam Krishnamurthy, MD has run 8 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Nebraska Medical Center
Nebraska Medicine-Bellevue
Clinical Trials Jairam Krishnamurthy, MD is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting
2 awards
Phase 3
19 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting
2 awards
Phase 3
19 criteria
More about Jairam Krishnamurthy, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Jairam Krishnamurthy, MD has experience with
- Fulvestrant
- Aromatase Inhibitor
- Alpelisib
- Multi-epitope HER2 Peptide Vaccine TPIV100
- Sargramostim
- Placebo
Breakdown of trials Jairam Krishnamurthy, MD has run
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jairam Krishnamurthy, MD specialize in?
Jairam Krishnamurthy, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Jairam Krishnamurthy, MD currently recruiting for clinical trials?
Yes, Jairam Krishnamurthy, MD is currently recruiting for 4 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Jairam Krishnamurthy, MD has studied deeply?
Yes, Jairam Krishnamurthy, MD has studied treatments such as Fulvestrant, Aromatase inhibitor, Alpelisib.
What is the best way to schedule an appointment with Jairam Krishnamurthy, MD?
Apply for one of the trials that Jairam Krishnamurthy, MD is conducting.
What is the office address of Jairam Krishnamurthy, MD?
The office of Jairam Krishnamurthy, MD is located at: University of Nebraska Medical Center, Omaha, Nebraska 68198 United States. This is the address for their practice at the University of Nebraska Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.